Centre for Transplant and Renal Research, Westmead Institute for Medical Research, Sydney, NSW, Australia.
Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
Front Immunol. 2021 Aug 26;12:717594. doi: 10.3389/fimmu.2021.717594. eCollection 2021.
Kidney transplantation is the most common solid organ transplant and the best current therapy for end-stage kidney failure. However, with standard immunosuppression, most transplants develop chronic dysfunction or fail, much of which is due to chronic immune injury. Tregs are a subset of T cells involved in limiting immune activation and preventing autoimmune disease. These cells offer the potential to provide tolerance or to allow reduction in immunosuppression in kidney transplants. The importance of Tregs in kidney transplantation has been shown in a number of seminal mouse and animal studies, including those with T cell receptors (TCRs) transgenic Tregs (TCR-Tregs) or Chimeric Antigen Receptor (CAR) Tregs (CAR-Tregs) showing that specificity increases the potency of Treg function. Here we outline the animal and human studies and clinical trials directed at using Tregs in kidney transplantation and other tolerance settings and the various modifications to enhance allo-specific Treg function and .
肾移植是最常见的实体器官移植,也是治疗终末期肾衰竭的最佳方法。然而,在标准免疫抑制下,大多数移植会出现慢性功能障碍或衰竭,其中大部分是由于慢性免疫损伤。调节性 T 细胞是 T 细胞的一个亚群,参与限制免疫激活和预防自身免疫性疾病。这些细胞有可能提供耐受性或允许减少肾移植中的免疫抑制。调节性 T 细胞在肾移植中的重要性已在许多重要的小鼠和动物研究中得到证实,包括那些具有 T 细胞受体 (TCR) 转基因调节性 T 细胞 (TCR-Tregs) 或嵌合抗原受体 (CAR) T 调节性 T 细胞 (CAR-Tregs) 的研究,表明特异性提高了 Treg 功能的效力。在这里,我们概述了旨在将调节性 T 细胞用于肾移植和其他耐受环境的动物和人体研究和临床试验,以及各种修饰方法,以增强同种异体特异性 Treg 功能。